Franklin Templeton Mutual Fund increased its stake in Akums Drugs and Pharmaceuticals Limited from 4.18% to 4.19%, acquiring 18,658 shares.
A contract development and manufacturing organization that produces pharmaceutical products for domestic and international clients. Established in 2004, Akums Drugs operates across multiple therapeutic areas and dosage forms, providing end-to-end manufacturing solutions including formulation development, clinical trial supplies, and commercial production. The company distinguishes itself through its vertically integrated operations, modern manufacturing facilities, and commitment to quality compliance across all operations.
Indian arm of Franklin Templeton Investments, a global AMC with over USD 1.5 trillion in assets worldwide. Manages over Rs 1.2 lakh crore in India. Navigated a significant setback when six debt schemes were wound up in April 2020 due to illiquid credit exposure, with full investor capital recovered by 2022. Equity franchise led by CIO Anand Radhakrishnan has maintained consistent performance through the volatility.
